Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor's "Product And Use" Lunesta Ad To Be "Very Visible," Company Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Sepracor's Lunesta (eszopiclone) "product and use" ad campaign will "be very visible going forward," the company said during its April 25 earnings call
Advertisement

Related Content

Sepracor Sees Reward In Lunesta Promotion Push
Sepracor Sees Reward In Lunesta Promotion Push
Takeda's Rozerem Will Not Be First-Line Competitor To Ambien, Sanofi Says
Takeda's Rozerem Will Not Be First-Line Competitor To Ambien, Sanofi Says
King Sonata DTC Campaign To Highlight Middle-Of-Night Dosing
Lunesta Has "Encouraging" Debut, Sepracor Says
Lunesta Has "Encouraging" Debut, Sepracor Says
Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon
Sepracor Plans April 4 Lunesta Launch
Sepracor Plans April 4 Lunesta Launch

Topics

Advertisement
UsernamePublicRestriction

Register

PS062072

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel